Prediction of carboplatin clearance calculated by patient characteristics or 24-hour creatinine clearance: A comparison of the performance of three formulae

Cancer Chemotherapy and Pharmacology

Volumn 42, Issue 4, 1998, Pages 307-312

  Okamoto, Hiroaki ^a   Nagatomo, Akira ^a   Kunitoh, Hideo ^a   Kunikane, Hiroshi ^a   Watanabe, Koshiro ^a  

^a YOKOHAMA MUNICIPAL CITIZEN'S HOSPITAL   (Japan)

Author keywords

AUC; Calvert; Carboplatin clearance; Chatelut; Prediction

Indexed keywords

CARBOPLATIN; ETOPOSIDE; IRINOTECAN;

AREA UNDER THE CURVE; ARTICLE; CALCULATION; CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; ENZYMATIC ASSAY; HUMAN; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; PREDICTION; PRIORITY JOURNAL;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; BODY WEIGHT; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CREATININE; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MODELS, STATISTICAL; SEX FACTORS;

EID: 0031856187     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050822     Document Type: Article

References (24)

1. Ando Y, Minami H, Ando M, Sakai S, Saka H, Shimokata K (1996) Risk of carboplatin overdosing when creatinine clearance is used in the Calvert formula (abstract). Proc Am Soc Clin Oncol 15: 179
2. Calvert AH, Harland SJ, Newell DR, Siddik ZH, Jones AC, McElwain TJ, Raju S, Wiltshaw E, Smith IE, Baker JM, Peckham MJ, Harrap KR (1982) Early clinical studies with cisdiammine-1,1-cyclobutanedicarboxylate platinum II. Cancer Chemother Pharmacol 9: 140
3. Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE, Siddik ZH, Judson IR, Gore ME, Wiltshaw E (1989) Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7: 1748
4. Calvert AH, Boddy A, Bailey NP, Siddiqui N, Humphreys A, Hughes A, Robson L, Gumbrell L, Thomas H, Chapman F, Proctor M, Simmons D, Oakey A, Lind MJ, Sinha DV, Newell DR (1995) Carboplatin in combination with paclitaxel in advanced ovarian cancer: dose determination and pharmacokinetic and pharmacodynamic interactions. Semin Oncol 22 [Suppl 12]: 91
5. Chatelut E, Canal P, Brunner V, Chevreau C, Pujol A, Boneu A, Roche H, Houin G, Bugat R (1995) Prediction of carboplatin clearance from standard morphological and biological patient characteristics. J Natl Cancer Inst 87: 573
6. Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16: 31
7. Egorin MJ, Van Echo DA, Tipping SJ, Olman EA, Whitacre MY, Thomson BW, Aisner J (1984) Pharmacokinetics and dosage reduction of cis-diammine(1,1-cyclobutanedicarboxylato)platinum in patients with impaired renal function. Cancer Res 44: 5432
8. Egorin MJ, Van Echo DA, Olman EA, Whitacre MY, Forrest A, Aisner J (1985) Prospective validation of a pharmacologically based dosing scheme for the cis-diamminedichloroplatinum(II) analogue diamminecyclobutanedicarboxylatoplatinum. Cancer Res 45: 6502
9. Jodrell DI, Egorin MJ, Canetta RM, Langenberg P, Goldbloom EP, Burroughs JN, Goodlow JL, Tan S, Wiltshaw E (1992) Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. J Clin Oncol 10: 520
10. Kearns CM, Belani CP, Erkmen K, Zuhowski M, Hiponia D, Zacharski D, Engstrom C, Ramanathan R, Trenn MR, Aisner J, Egorin MJ (1995) Pharmacokinetics of paclitaxel and carboplatin in combination. Semin Oncol 22 [Suppl 12]: 1
11. Kunitoh H, Watanabe K, Nagatomo A, Okamoto H, Kimbara K (1997) Concurrent daily carboplatin and accelerated thoracic radiotherapy in locally advanced non-small cell lung cancer. Int J Radiat Oncol Biol Phys 37: 103
12. Langer CJ, Leighton JC, Comis RL, O'Dwyer PJ, McAleer CA, Bonjo CA, Engstrom PE, Litwin S, Ozols RF (1995) Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysis. J Clin Oncol 13: 1860
13. Laurence JCW, Sjoerd R, Wim WBH, Robert AAM, Jos HB (1996) Evaluation of formulas using the serum creatinine level to calculate the optimal dosage of carboplatin. Cancer Chemother Pharmacol 37: 266
14. LeRoy AF, Wehling ML, Sponseller HL, Friauf WS, Solomon RE, Dedrick RL (1977) Analysis of platinum in biological materials by flameless atomic absorption spectrophotometry. Biochem Med 18: 184
15. Loo JCK, Riegelman S (1970) Assessment of pharmacokinetics constants from postinfusion blood curves obtained after i.v. infusion. J Pharm Sci 59: 53
16. Newell DR, Eeles RA, Gumbrell LA, Boxall FE, Horwich A, Calvert AH (1989) Carboplatin and etoposide pharmacokinetics in patients with testicular leratoma. Cancer Chemother Pharmacol 23: 367
17. Okamoto H, Nagatomo A, Kunitoh H, Watanabe K (1995) A combination phase I-II study of carboplatin, irinotecan plus G-CSF with the Calvert equation in patients with advanced non-small cell lung cancer (NSCLC) (abstract). Proc Am Soc Clin Oncol 14: 373
18. Ottaway JH (1973) Normalization in the fitting of data by iterative methods: application to tracer kinetics and enzyme kinetics. Biochem J 134: 729
19. Sorensen BT, Stromgren A, Jakobsen P, Jakobsen A (1991) Dose toxicity relationship of carboplatin in combination with cyclophosphamide in ovarian cancer patients. Cancer Chemother Pharmacol 28: 397
20. Sorensen BT, Stromgren A, Jakobsen P, Nielsen JT, Andersen LS, Jakobsen A (1992) Renal handling of carboplatin. Cancer Chemother Pharmacol 30: 317
21. Sorensen BT, Stromgren A, Jakobsen P, Jakobsen A (1993) Is creatinine clearance a sufficient measure for GFR in carboplatin dose calculation? (abstract). Eur J Cancer 29: s110
22. Vijgh WJF van der (1991) Clinical pharmacokinetics of carboplatin. Clin Pharmacokinet 21: 242
23. Wada T, Nakamura T, Maeda Y, Maruyama H, Onishi Y, Hatae M (1996) Actual carboplatin AUC had better correlation with Chatelut's formula than arranged Calvert's formula using 24-hr creatinine clearance (abstract). Proc Am Soc Clin Oncol 15:475
24. Watanabe K, Okamoto H, Nagatomo A, Kunitoh H (1995) Carboplalin (CBDCA) combined with etoposide (VP) in the treatment of poor-risk small cell lung cancer (SCLC): a phase II study based on a pharmacokinetieally guided dose schedule (abstract). Proc Am Soc Clin Oncol 14: 372